Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 8,312,100 | 6,960,000 | 7,301,801 | 6,941,600 | 6,488,000 |
| Cost of Goods | 1,807,400 | 1,626,700 | 1,548,100 | 1,579,100 | 1,430,500 |
| Gross Profit | 6,504,700 | 5,333,300 | 5,753,700 | 5,362,500 | 5,057,500 |
| Operating Expenses | 4,379,400 | 3,840,000 | 3,917,399 | 3,686,100 | 3,847,900 |
| Operating Income | 2,125,700 | 1,494,000 | 1,836,400 | 1,676,500 | 1,210,100 |
| Other Income | -36,800 | 35,700 | 260,000 | -111,000 | -119,200 |
| Pre-tax Income | 2,088,900 | 1,529,700 | 2,096,400 | 1,565,500 | 1,090,900 |
| Income Tax | 325,700 | 184,800 | 158,700 | 113,800 | 138,400 |
| Net Income Continuous | 1,763,200 | 1,344,900 | 1,937,699 | 1,451,700 | 952,500 |
| Net Income | $1,763,200 | $1,344,900 | $1,937,699 | $1,451,700 | $952,500 |
| EPS Basic Total Ops | 1.96 | 1.49 | 2.15 | 1.61 | 1.06 |
| EPS Basic Continuous Ops | 1.96 | 1.49 | 2.15 | 1.61 | 1.06 |
| EPS Diluted Total Ops | 1.95 | 1.49 | 2.14 | 1.61 | 1.05 |
| EPS Diluted Continuous Ops | 1.95 | 1.49 | 2.14 | 1.61 | 1.05 |
| EPS Diluted Before Non-Recurring Items | 2.11 | 1.62 | 2.09 | N/A | N/A |
| EBITDA(a) | $2,492,000 | $1,856,300 | $2,211,401 | $2,039,401 | $1,559,000 |